API manufacturer Cambrex Corporation has completed its acquisition of contract development manufacturer Avista Pharma Solutions.
Cambrex said the move strengthens its position as a fully integrated small molecule contract development and manufacturing organisation (CDMO) across the entire drug lifecycle.
Announced back in November 2018, the deal will see Avista’s four sites – located in Durham, NC; Longmont, CO; Agawam, MA, and Edinburgh, Scotland – integrated into Cambrex’s global network.
“Acquiring Avista adds a full complement of early stage development capabilities to Cambrex’s larger scale capabilities for both APIs and finished dosage forms,” said Steve Klosk, President and CEO of Cambrex.
“Adding Avista today and Halo Pharma in September significantly increases our customer base and funnel of projects, provides significant cross selling opportunities and allows us to offer an integrated service offering for most small molecules from the pre-clinical stage through the commercial stage.”
In September 2018, Cambrex acquired Halo Pharma, adding formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.
With the acquisition of Avista, Cambrex now operates 12 facilities around the globe and employs approximately 2,000 people.